Li-jung W. Tai

Endocrinology
3350 La Jolla Village Dr
San Diego, CA 92161

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

Journal: The New England journal of medicine
Published: February 18, 2026

Delpacibart Etedesiran Improves the Molecular Pathology of Myotonic Dystrophy Type 1 in the Phase 1/2 MARINA® Study.

Delpacibart Etedesiran Improves the Molecular Pathology of Myotonic Dystrophy Type 1 in the Phase 1/2 MARINA® Study.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 07, 2025

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 07, 2025

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.

Journal: Neurology and therapy
Published: December 02, 2020

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.

Journal: ESC heart failure
Published: August 06, 2020

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.

Journal: Nucleic acid therapeutics
Published: February 12, 2020

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Journal: Diabetes care
Published: June 21, 2018

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Journal: The New England journal of medicine
Published: May 25, 2017

Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.

Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.

Journal: Current diabetes reviews
Published: December 22, 2015

Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development.

Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development.

Journal: Current diabetes reviews
Published: November 17, 2014

Higher mortality in patients with right hemispheric intracerebral haemorrhage: INTERACT1 and 2.

Higher mortality in patients with right hemispheric intracerebral haemorrhage: INTERACT1 and 2.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: November 06, 2014

Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-δ gene.

Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-δ gene.

Journal: American journal of physiology. Heart and circulatory physiology
Published: February 04, 2014
Showing 1-12 of 12

Last Updated: 09/26/2026